CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner.
CXCL14
chemokines
immune profiles
triple-negative breast cancer
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Aug 2022
18 Aug 2022
Historique:
received:
29
06
2022
revised:
03
08
2022
accepted:
06
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is aggressive and has a poor overall survival due to a lack of therapeutic targets compared to other subtypes. Chemokine signature revealed that TNBC had low levels of CXCL14, an orphan homeostatic chemokine to regulate the immune network. Here, we investigated if CXCL14 plays a critical role in TNBC progression, focusing on survival rates, tumor growth and metastasis, and immune profiles in the tumor microenvironment. Analysis of human breast-cancer datasets showed that low
Identifiants
pubmed: 36012586
pii: ijms23169314
doi: 10.3390/ijms23169314
pmc: PMC9409254
pii:
doi:
Substances chimiques
CXCL14 protein, human
0
CXCL14 protein, mouse
0
Chemokines, CXC
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : Intramural program funding
Pays : United States
Références
Front Immunol. 2020 Oct 05;11:561404
pubmed: 33123134
Cells. 2019 Aug 22;8(9):
pubmed: 31443516
Breast Care (Basel). 2017 Jul;12(3):152-158
pubmed: 28785182
Cancers (Basel). 2021 Apr 01;13(7):
pubmed: 33915941
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Int Immunopharmacol. 2021 Aug;97:107681
pubmed: 33932697
Pharmacol Res. 2020 Mar;153:104683
pubmed: 32050092
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
Nat Commun. 2021 Nov 1;12(1):6276
pubmed: 34725325
Arch Physiol Biochem. 2020 Jun 17;:1-7
pubmed: 32552011
Cell Biochem Funct. 2020 Jul;38(5):613-620
pubmed: 32077118
Nature. 2020 Sep;585(7823):135-140
pubmed: 32610344
J Inflamm (Lond). 2016 Jan 05;13:1
pubmed: 26733763
Breast Cancer Res. 2010;12(5):R85
pubmed: 20946665
Cancer Res. 2015 Dec 15;75(24):5283-98
pubmed: 26483204
Theranostics. 2017 Feb 8;7(4):855-875
pubmed: 28382159
J Invest Dermatol. 2020 Jul;140(7):1327-1334
pubmed: 31881212
Oncogene. 2019 Nov;38(46):7166-7180
pubmed: 31417179
Int J Oncol. 2014 Apr;44(4):1316-24
pubmed: 24534874
NPJ Breast Cancer. 2018 Mar 20;4:7
pubmed: 29582015
Mol Med Rep. 2014 Sep;10(3):1561-8
pubmed: 24938992
Int J Mol Sci. 2017 Feb 07;18(2):
pubmed: 28178200
Mediators Inflamm. 2020 Mar 31;2020:2431705
pubmed: 32317861
Immune Netw. 2018 Aug 13;18(4):e29
pubmed: 30181917
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
Front Public Health. 2020 Dec 22;8:576964
pubmed: 33415093
Sci Rep. 2015 Mar 13;5:9083
pubmed: 25765541
Breast Cancer Res Treat. 2012 Oct;135(3):725-35
pubmed: 22910931
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
Clin Cancer Res. 2022 Jul 1;28(13):2898-2910
pubmed: 35511927
Arch Gynecol Obstet. 2016 Feb;293(2):247-69
pubmed: 26341644
Clin Cancer Res. 2008 Sep 1;14(17):5357-67
pubmed: 18765527
JAMA Surg. 2017 May 1;152(5):485-493
pubmed: 28355428
J Transl Med. 2013 Jan 07;11:6
pubmed: 23294544
Nat Genet. 2021 Sep;53(9):1334-1347
pubmed: 34493872
Prostate. 2005 Jun 15;64(1):67-74
pubmed: 15651028
Oncotarget. 2018 Jun 29;9(50):29286-29303
pubmed: 30034618
Breast. 2017 Aug;34 Suppl 1:S27-S30
pubmed: 28668293
J Mol Biol. 2006 Nov 3;363(4):813-22
pubmed: 16987528
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925